is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Atomo Diagnostics will be showcasing their range of innovative, user-centred rapid diagnostic test platforms at Arab Health 2023.
A global leader in the user-centred design of innovative, accurate and reliable rapid diagnostics, the company will be joining the ABHI UK Pavilion to demonstrate how their simple and low-cost solutions can deliver better user experience, more accurate results and better healthcare outcomes.
Atomo Diagnostics is the first company in the world to bring human-centred engineering to the heart of diagnostics design. The company has developed a unique technology based on the philosophy that fast, accurate point of care testing should be simple and intuitive, focusing on how diagnostic tests operate in the hands of users to improve ease of use and reduce error rates.
The recipient of multiple international design awards, Atomo creates devices that address the problems commonly associated with standard multi-component rapid diagnostic test kits.
Atomo’s Rapid Diagnostic Test (RDT) platforms offer all-in-one convenience with a built-in safety lancet, unique sample collection feature, single action sample and
buffer delivery system, and interlocked user steps. The innovative design and built-in features of Atomo’s products are designed to make them simpler to use than standard multi-component test kits, with less scope for user errors.
The company offers the world’s first integrated, blood-based rapid diagnostic test (RDT) for HIV screening, recognised globally for its design, performance and ease-of-use, with an accuracy of 99.6%. Their extensive product range also encompasses accurate point of care diagnostic platforms that can be used in testing for infectious diseases such as COVID-19, allergy sensitivities, wellness, women’s health, men’s health, sexual health, heart health and other applications.
Atomo has recently introduced a Swab Platform to market, which expands their product range beyond blood-based testing and has been developed to improve usability and performance of traditional swab-based rapid tests.
Their products are currently approved for distribution in over 40 countries.
John Kelly, CEO of Atomo Diagnostics, commented: “Our innovative rapid test solutions deliver unmatched usability and simplicity in point-of-care testing, and have demonstrated excellent performance for both professional and home use. Our flagship HIV Self Test is prequalified by the WHO and registered in more than 20 countries. Beyond HIV, Atomo works with partners to commercialise tests on its devices for other applications, with commercialised tests delivering early detection of pregnancy and differentiating between viral and bacterial infection in primary care settings. Our unique devices and functionality are increasingly being recognised as a solution to decentralised testing needs and we continue to seek partners looking to improve the usability and performance of their POC tests. We are excited to be joining ABHI at this year’s Arab Health Exhibition where we look forward to showcasing our innovative products and technologies, as well as making new connections and forming new partnerships with global distributors.”
The Arab Health Exhibition & Congress is taking place from 30 January – 2 February 2023 at the Dubai Convention and Exhibition Centre. Throughout the exhibition, Atomo Diagnostics will be located on the ABHI UK Pavilion – Hall 2, Stand H50.
ABHI is the UK’s leading industry association for health technology (HealthTech).
ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium sized enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is the largest employer in the broader Life Sciences sector, employing 145,700 people in 4,350 companies, with a combined turnover of £30bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 330 members account for approximately 80% of the sector by value.